Clinical trials: sponsored by Merck Sharp & Dohme LLC
Vaccine Refusal, Vaccine-Preventable Diseases
Improving Vaccine Counseling Skills Among Residents Using Educational Modules and Standardized Patient Encounters
Unfortunately, only 40% of US pediatric residency programs reported in a survey that vaccine safety and counseling training is provided to residents.
- Conditions
- Vaccine Refusal, Vaccine-Preventable Diseases, Physician-Patient Relations
- Trial name
- NCT06074237
- Testing
- Immersive resident education, Standardized patient (SP) encounter
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Corewell Health East
Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
This is a multi-center, open-label, phase 1 dose escalation and expansion study evaluating the safety, anti-tumor effect, and immunogenicity of CUE-101 as monotherapy treatment in second line or CUE-101 Combination Therapy with…
- Conditions
- Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma
- Trial name
- NCT03978689
- Testing
- CUE-101, KEYTRUDA®, Pembrolizumab
- Where
- 17 sites in United States
- Volunteers
- 80 people
- Sponsor
- Cue Biopharma
Pulmonary Vascular Disorder, Primary Pulmonary Hypertension
Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
This is a randomized, double-blind, placebo-controlled, multicenter, multinational study investigating the effect of riociguat (MK-4836) in patients with early pulmonary vascular disease.
- Conditions
- Pulmonary Vascular Disorder, Primary Pulmonary Hypertension, Systemic Sclerosis, Other Systemic Involvement of Connective Tissue
- Trial name
- ESRA (NCT05339087)
- Testing
- Riociguat Oral Tablet
- Where
- 8 sites in Austria, France and 4 more
- Volunteers
- 35 people
- Sponsor
- Heidelberg University
Pneumonia, Hematologic Malignancy
Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation
The goal of this clinical trial is to learn whether the antibiotic ceftolozane-tazobactam works to treat serious Pseudomonas aeruginosa infections in people with blood cancers or who received a stem cell transplant.
- Conditions
- Pneumonia, Hematologic Malignancy, Pseudomonas Aeruginosa Infection, Bacteremia
- Trial name
- NCT04673175
- Testing
- Ceftolozane / Tazobactam Injection
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Weill Medical College of Cornell University
Non-Small Cell Lung Cancer
Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
This is an open label, multi-institutional, single arm study with a dose escalation phase Ib cohort, followed by a phase II cohort of pembrolizumab and Imprime PGG. No randomization or blinding is involved.
- Trial name
- NCT03003468
- Testing
- Imprime PGG, MK-3475
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Lawrence Feldman, MD
Head and Neck Squamous Cell Carcinoma (HNSCC)
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
This phase II trial with a safety run-in component will evaluate whether the addition of pembrolizumab to Stereotactic Body Radiation Therapy (SBRT) re-irradiation will improve the progression-free survival for patients with…
- Trial name
- KEYSTROKE (NCT03546582)
- Testing
- Pembrolizumab, Stereotactic Body Radiation Therapy (SBRT)
- Where
- 18 sites in United States, Canada
- Volunteers
- 86 people
- Sponsor
- RTOG Foundation, Inc.
Healthy
A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)
The goal of this study is to learn how safe V118 Formulation C is in Healthy Adults and how well people tolerate it.
- Trial name
- NCT06611033
- Testing
- V118C, V118, PREVNAR 20™
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Primary Glioblastoma
Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma
Glioblastomas (GBM) are the most frequent brain tumors and one of the most lethal adult cancers despite maximal multimodal therapy.
- Trial name
- MATVAC-1 (NCT07347210)
- Testing
- UCPVax, Pembrolizumab, Temozolomide
- Where
- 4 sites in France
- Volunteers
- 98 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Invasive Breast Cancer, Metastatic Breast Cancer
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
This research study is evaluating the safety and effectiveness of Sacituzumab Govitecan with or without Pembrolizumab in metastatic HR+/HER2- breast cancer.
- Conditions
- Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
- Trial name
- NCT04448886
- Testing
- Pembrolizumab, Sacituzumab Govitecan
- Where
- 8 sites in United States
- Volunteers
- 110 people
- Sponsor
- Ana C Garrido-Castro, MD
Delirium in Old Age
REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant
This research study will evaluate the effectiveness of postoperative administration of a drug called suvorexant, to improve postoperative sleep and decrease the severity of delirium (serious confusion) in adults 65 years and…
- Trial name
- REPOSE (NCT05733286)
- Testing
- Suvorexant 20 mg
- Where
- United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Duke University
Bladder Cancer
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Researchers are looking for new ways to treat people with high-risk muscle-invasive urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bladder cancer that begins in cells that line the inside of the bladder and other…
- Trial name
- NCT06305767
- Testing
- Pembrolizumab, Intismeran autogene, Enfortumab Vedotin
- Where
- 74 sites in United States, Australia and 14 more
- Volunteers
- 230 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006)
The goal of this study is to learn how [14C]ulonivirine moves through a healthy person's body over time. Researchers will study how [14C]ulonivirine is absorbed by the body, broken down by the body, and how it leaves the body.
- Trial name
- NCT07334886
- Testing
- [14C]Ulonivirine
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Ebola
African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola
This is a randomized, placebo-controlled, multi-site, double-blind trial of V920 (rVSVΔG-ZEBOV-GP) Ebola Virus vaccine candidate in subjects with HIV infection to be conducted in conformance with Good Clinical Practices.
- Trial name
- NCT03031912
- Testing
- V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine, Saline
- Where
- Canada
- Volunteers
- 251 people
- Sponsor
- Canadian Immunization Research Network
Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH).
- Conditions
- Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease
- Trial name
- NCT05877547
- Testing
- Efinopegdutide, Semaglutide
- Where
- 175 sites in United States, Austria and 24 more
- Volunteers
- 381 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV, HIV Pre-exposure Prophylaxis
Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)
This double-blind, placebo-controlled study was designed to assess the safety, tolerability, and pharmacokinetics of oral MK-8527 taken once monthly (QM) in participants at low risk for human immunodeficiency virus Type 1 (HIV-1)…
- Trial name
- NCT06045507
- Testing
- MK-8527
- Where
- 18 sites in United States, Israel and 1 more
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Invasive Bladder Cancer
Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer
PLUMMB is an phase I trial to investigate the safety, tolerability and effectiveness of an immunotherapy drug called Pembrolizumab used in combination with radiotherapy.
- Trial name
- PLUMMB (NCT02560636)
- Testing
- Pembrolizumab, Radiotherapy
- Where
- United Kingdom
- Volunteers
- 34 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Solid Tumor
JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
This study is to evaluate the safety and tolerability of JAB-BX102 monotherapy and combination therapy with pembrolizumab in adult participants with advanced solid tumors.
- Trial name
- NCT05174585
- Testing
- JAB-BX102 (anti-CD73 monoclonal antibody), pembrolizumab (anti-PD-1 monoclonal antibody)
- Where
- 6 sites in China
- Volunteers
- 21 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Solid Tumor
A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors
Phase I with a dose finding cohort, followed by expansion cohorts in pre-specified tumor types.
- Trial name
- POP-ART (NCT06337630)
- Testing
- PLX038 + Tuvusertib
- Where
- 2 sites in France
- Volunteers
- 10 people
- Sponsor
- Institut Curie
Breast Cancer
Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
- Trial name
- NCT03393845
- Testing
- Pembrolizumab, Fulvestrant
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Nancy Chan, MD
Advanced and Metastatic Urothelial Cancer
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
The purpose of the trial is to evaluate the antitumor activity and confirm the safety for the combination of Fibroblast Growth Factor Receptor (FGFR) inhibitor futibatinib and anti-programmed cell death-1 (PD-1) antibody…
- Trial name
- NCT04601857
- Testing
- Futibatinib, Pembrolizumab
- Where
- 18 sites in United States, France and 1 more
- Volunteers
- 43 people
- Sponsor
- Taiho Oncology, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.